Forearm and systemic adipose tissue free fatty acid (FFA) release was measured in eight nonobese, six lower-body obese, and eight upper-body obese women under basal, hyperinsulinemic, and hypoinsulinemic conditions to determine whether forearm fat is regulated in a similar manner as whole body fat. Results: Adipose tissue palmitate release was greater from forearm than whole body (5.97±0.75 vs. 3.84±0.34 gmol -kg far' -min-', respectively, P < 0.005, n = 22 subjects). Systemic palmitate release, relative to fat mass, was significantly (P < 0.01) greater in nonobese than upper-body obese, and upper-body obese than lower-body obese women, and forearm adipose tissue palmitate release followed the same pattern. Hyperinsulinemia suppressed systemic and forearm lipolysis to similar degrees, however, hypoinsulinemia consistently increased systemic palmitate flux without increasing forearm palmitate release. These results confirm the heterogeneity of adipose tissue in an in vivo model and emphasize the need to consider which adipose tissue depots are responsible for the differences in systemic FFA flux in obese and nonobese humans. (J. Clin. Invest. 1991. 87:187-193.).
Introduction
Upper-body obesity is more likely to result in adverse health consequences than lower body obesity (1, 2) . The reasons for these differences are unknown; however, the increased free fatty acid (FFA) availability in upper body obesity (3) could contribute to the hypertriglyceridemia (4) and insulin resistance (5, 6) seen in this condition. This greater FFA flux could result from either accelerated lipolysis in specific adipose tissue depots or from all body fat equally. Plasma FFA concentrations correlate best with abdominal adipocyte lipolysis in vitro (7); thus, increased amounts ofupper body fat could be primarily responsible for the increased FFA flux in upper body obesity.
Upper-body and lower-body adipocytes differ in several respects. Physiologic catecholamines increase lipolysis in fat cells from arm (8) , omental (9) , and abdominal subcutaneous depots (9, 10), but not those from gluteal/thigh regions (8) (9) (10) .
tivity of upper-body fat cells compared with lower-body fat cells (10) . In addition, abdominal adipocytes are sensitive to insulin in vitro (1 1), whereas gluteal adipocytes show little (12) or no (13) antilipolytic response to insulin. Whether anatomically separate adipose tissue depots have different lipolytic rates or responses to insulin in vivo, however, is unknown.
The following studies were designed to determine whether differences in adipose tissue lipolytic properties are present in vivo. Basal, insulin-suppressed and insulin-withdrawn FFA release from forearm fat was compared with total body FFA release. Forearm and body fat mass were quantified to allow comparisons relative to fat content. In addition, three groups of women with different adipose tissue lipolytic rates were included in order to directly compare upper-body extremity adipose tissue FFA release. The results confirm that heterogeneity of adipose tissue lipolysis does occur in vivo.
Methods
Subjects. Informed, written consent was obtained from 14 healthy, moderately obese (body mass index 30-36 kg/m2) premenopausal women and eight nonobese premenopausal women. The obese women were selected such that six had waist/hip ratios < 0.76 and eight had waist/hip ratios > 0.85 (14) . The waist circumference was measured at the natural (smallest) waist with the subject in the supine position, and the hip measurement was made at the maximum circumference with the subject standing with their feet together. All women had maintained a stable weight for > 2 mo before the study and were instructed to consume > 200 g of carbohydrate daily for at least 2 wk before the study. To determine whether upper body extremity (forearm) adipose tissue lipolysis differs between obese individuals with different systemic lipolytic rates upper-body obese and lower-body obese women were intentionally selected to have different palmitate flux values. One ofthe obese women participated in a previous study (3) and others were recruited during participation in ongoing studies ofbody fat distribution. A summary of the subjects' clinical characteristics, serum lipids, and body composition is given in Table I The serum triglyceride concentrations were greater in upper body obese women (P < 0.001) than lower-body obese or nonobese women, whose concentrations were not different from each other. Nonobese women had less body fat (P < 0.001) and fat-free mass (P < 0.01) than either group ofobese women. Forearm fat content was less (P < 0.001) in nonobese women than lower-body obese or upper-body obese women. The baseline plasma insulin concentrations were greater in upper body obese women (P < 0.001) than nonobese or lowerbody obese women, whereas plasma growth hormone concentrations were greatest in nonobese women (P < 0.05). Baseline plasma glucagon concentrations were not statistically different.
Plasma hormone concentrations. During the insulin infusion, plasma insulin concentrations increased in each group of subjects (Table II) with no significant changes in plasma glucagon or growth hormone concentrations. During the somatostatin infusion plasma insulin concentrations decreased to comparable values in each group of subjects. Because glucagon was not infused (27) women. The hypoinsulinemia created by somatostatin infusion resulted in an 80-86% increase (P < 0.001) in palmitate flux in each group. Although total palmitate flux during hypoinsulinemia was greater (P = 0.02) in upper-body obese women than lower-body obese or nonobese women, when corrected for lean body mass these differences were no longer statistically significant (P = 0.06 vs. nonobese, P = 0.12 vs. lower-body obese). Forearm palmitate kinetics. Total forearm plasma flow during the baseline study interval was similar in upper-body obese, lower-body obese, and nonobese women (41±5 vs. 48±5 vs. 36±5 ml/min, respectively, P = NS). Forearm plasma flow remained relatively constant in these three study groups during the hyperinsulinemic (41±4, 43±7, and 36±5 ml/min, respectively) and the hypoinsulinemic (35±4, 41±5, and 27±5 ml/ min, respectively) study intervals.
Forearm palmitate uptake was not significantly different between the three study groups during the baseline, hyperinsulinemic, or hypoinsulinemic study intervals (Table III) . Hyperinsulinemia decreased plasma palmitate concentrations and forearm palmitate uptake similarly in each group. Although plasma palmitate concentrations increased dramatically during the hypoinsulinemic study interval, palmitate uptake by forearm did not increase significantly.
Total forearm palmitate release during the baseline interval was not significantly different between the three groups and represented -1.3% of systemic palmitate release. When corrected for the forearm and whole body fat content, baseline release (all subjects, n = 22) was greater (P < 0.005) from forearm fat than from total body fat (5.79±0.75 vs. 3.84±0. 34 ,umol * kg fat' * min-', respectively). Similar trends were seen in each group (Table IV) . Forearm adipose tissue palmitate release, when expressed per unit fat mass, was greater in nonobese women than lower-body obese (P < 0.05) or upper body obese women (0. 10 > P > 0.05). Because ofthe selection criteria for obese subjects systemic palmitate release per kilogram of fat mass was greater (P < 0.01) in upper-body obese women than lower-body obese women by -28%. Although not statistically different, palmitate release per kilogram of forearm fat was also 27% greater in upper-body obese women than lowerbody obese women.
Hyperinsulinemia reduced systemic palmitate release by 40%, 56%, and 28% in nonobese, lower-body obese, and upperbody obese women, respectively, with comparable decrements in forearm palmitate release (34%, 39%, and 33%, respectively) (Table III) . When the data from all 22 subjects was analyzed, forearm adipose tissue palmitate release during hyperinsulinemia remained greater than total body adipose tissue palmitate release (3.90±0.58 vs. 2.33±0.25 timol -kg fat' -min-', P <0.005).
In contrast, hypoinsulinemia changed forearm and systemic palmitate release in opposite directions. Systemic palmitate flux was greater during hypoinsulinemia than during the baseline (Tables III and IV) , while forearm palmitate release was less (0.93±0.17 vs. 1.34±0.16 ,umol min-', P < 0.05, n = 20 subjects). This decrease in forearm palmitate release was not equally apparent in each group, however, with a statistically significant (P < 0.05) reduction in nonobese women, but not in lower-body obese (P = 0.14), or in upper-body obese (P = 0.92) women. 
Discussion
These study results provide strong evidence that regional variations in human adipose tissue lipolysis occur in vivo, supporting and extending the observations ofAmer et al. (28) . Relative to the quantity of adipose tissue, forearm fat released greater amounts of FFA than body fat as a whole, suggesting either inherent differences in arm fat cells (8) , or the forearm hormonal milieu. Forearm palmitate release was measured in three groups of women selected to have different whole-body adipose tissue lipolytic rates. In each group forearm adipose tissue palmitate release more closely approximated their systemic palmitate flux than it did a generic forearm lipolytic rate common to the three groups. Mild hyperinsulinemia suppressed forearm and systemic lipolysis to similar degrees, suggesting that forearm adipose tissue retains the insulin responsiveness of upper-body fat (1 1). Despite this, somatostatin-induced hypoinsulinemia did not increase forearm FFA release as it did from nonforearm adipose tissue depots. Thus, hypoinsulinemia permits accelerated lipolysis in a heterogeneous manner in vivo. The conclusion that forearm adipose tissue is more lipolytically active than total body adipose tissue is dependent upon the measurement accuracy of plasma palmitate concentration and SA, forearm blood flow, and adipose tissue mass. The accuracy and precision of the palmitate concentration and specific activity assay is known to be excellent (16, 17) . In this study capacitance plethysmography provided forearm blood flow and FFA release values similar to those observed in previous reports in which blood flow was measured using dye dilution techniques (29, 30) . A DPX (24) was used to measure forearm fat content. This technique employs the same principles as dual-photon absorptiometry, a method that provides excellent results when compared with other, independent measures of body fat in humans (25) . Ifforearm fat content in these subjects was systematically underestimated by -50%, forearm adipose tissue lipolysis would equal total body adipose tissue lipolysis. This magnitude oferror is inconsistent with results observed by us and others (24, 25) for this technique. In addition, the percentage of forearm fat found in the present study (-18% in nonobese women and -25% in obese women) is actually greater than the usually quoted figure (26) . Thus, the conclusion that forearm adipose tissue is more lipolytically active than total body adipose tissue on a weight basis appears sound.
The present study, while confirming that forearm adipose tissue exhibits lipolytic differences compared with nonforearm adipose tissue, cannot distinguish whether this results from its peripheral versus central or upper body versus lower body characteristics. The latter hypothesis is supported by the finding of catecholamine responses from arm adipocytes in vitro (8) , and the finding of insulin responsiveness in the forearm adipose tissue in the present study, a characteristic of upperbody fat cells (11) . In addition, studies from our laboratory have demonstrated lipolytic differences in lower-body (leg) and upper-body fat (31) . Basal upper-body palmitate release in these unselected upper-body obese, lower-body obese, and nonobese women in that study is similar to basal forearm palmitate release observed in the comparable groups in the present study (M. L. Martin and M. D. Jensen, unpublished data). Thus, forearm adipose tissue may be a model for the study of upper body adipose tissue in vivo, however, further studies will be needed to more directly test this hypothesis.
Nonobese, upper-body obese, and lower-body obese women with markedly different lipolytic rates per unit fat mass were intentionally selected for these experiments. This study design permits the comparison of upper-body extremity adipose tissue lipolysis among the different groups in relationship to total body adipose tissue lipolytic rates. If there was no intrinsic difference in upper-body extremity adipocytes between individuals, forearm adipose tissue palmitate release (per unit fat mass) should be similar in each group. Instead, forearm adipose tissue lipolysis was greatest in nonobese women, least in lower-body obese women, and intermediate in upper-body obese women, a pattern identical to that observed for total body fat. Ifforearm fat is representative ofupper body fat, these results suggest that factors in addition to the quantity of upper body fat are important in determining systemic lipolysis.
In contrast with the findings of the present study, basal lipolysis from upper-body adipocytes in vitro has been found to be less than or equal to that in lower-body adipocytes (7) (8) (9) (10) . Differences in endogenous catecholamine (8-10) effects on lipolysis between upper and lower body fat cells may account for the greater FFA release from forearm adipose tissue compared with total body adipose tissue. The f3-adrenergic stimulatory effects of physiologic catecholamines predominate in upper body adipocytes (9) , while the a2-adrenergic inhibitory effects are equally important in lower body adipocytes (9, 10) . Recent in situ studies of the adrenergic regulation of abdominal and gluteal adipose tissue lipolysis confirm the presence of regional differences in vivo (28) . Resting adrenergic tone might account for the differences seen in the present study by selectively increasing FFA release from upper body extremity fat. These results underscore the difficulty in extrapolating in vitro results to the in vivo situation unless careful consideration ofthe local environment is taken into consideration.
Hyperinsulinemia suppressed lipolysis in forearm and total-body adipose tissue similarly, but hypoinsulinemia did not permit the expected increase in forearm lipolysis as it did systemic lipolysis. Although the etiology ofthis discrepancy is not known, failure to increase forearm blood flow may have contributed to this effect. Increased FFA concentrations can inhibit lipolysis (32) , and either increased FFA delivery or decreased removal of locally produced FFA may have inhibited forearm lipolysis. Whether the modest blood flow reductions observed were caused by local vasoconstriction secondary to high FFA/albumin ratios (33), a direct effect of the somatostatin, or hypoinsulinemia itself is unknown. Failure to increase forearm blood flow also might theoretically result in an apparent decrease in FFA release because ofpreferential adipocyte reesterification of unlabeled FFA present in the periadipocyte extracellular fluid. Why this would affect forearm adipose tissue more so than other depots is not known. Clearly, in vivo hormonal changes may not affect all fat cells in the expected manner because of the complex changes in their environment.
It is important to note that although FFA flux is generally related to lean body mass (3, 34) , the tissues known to consume FFA as a metabolic fuel, this report has extensively expressed palmitate release per unit fat mass. This was done in order to allow the comparison of adipose tissue lipolysis from different body fat stores within the same individual and to compare these relationships between groups of subjects with different lipolytic rates. When reporting systemic FFA kinetic data in studies of obesity from a perspective of fuel metabolism it would still appear best to express FFA availability relative to lean body mass.
It is not possible to directly compare the effects ofinsulin on systemic lipolysis between the three groups of subjects in this study because of the different plasma insulin concentrations obtained during the hyperinsulinemic study interval. Somatostatin infusion, however, resulted in similar plasma insulin concentrations and similar proportional increases in palmitate flux in each group. During hypoinsulinemia palmitate flux remained greater in upper-body obese women than the other two groups, perhaps related to the greater baseline palmitate flux. Thus, insulin withdrawal resulted in similar increments in lipolysis independent of adipose tissue stores, with lower-body obese and nonobese women continuing to remain similar, and upper-body obese women maintaining a greater total palmitate release. Ifbasal insulin availability is the only factor restraining lipolysis, FFA flux might increase in proportion to adipose tissue stores during insulin withdrawal. Local inhibition oflipolysis by adenosine (35) or FFA themselves (32) may restrain lipolysis during hypoinsulinemia and prevent excessive FFA release even when fat mass is increased by two-to threefold.
In summary, these studies have demonstrated for the first time differences in adipose tissue lipolytic rates in different tissue beds in vivo. The findings are consistent with in vitro data if the variable of adrenergic effects on upper and lower body fat cells (8) (9) (10) are taken into account. Forearm adipose tissue palmitate release varied in proportion to systemic adipose tissue palmitate release. Although forearm adipose tissue responds to hyperinsulinemia in much the same manner as total-body adipose tissue, hypoinsulinemia, when created by somatostatin infusion, does not permit increased mobilization of forearm adipose tissue fatty acids. These results support the concept of inherent regional differences in human adipocytes and suggest the need to consider that different adipose tissue beds may contribute to abnormal regulation of lipolysis in certain disease states.
